Trevi Therapeutics (TRVI) Preferred Stock Liabilities (2018 - 2019)
Trevi Therapeutics' (TRVI) quarterly Preferred Stock Liabilities came in at $21.2 million in Q1 2019, down 37.16% quarter-over-quarter from $33.7 million in Q4 2018.
Trevi Therapeutics (TRVI) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Trevi Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $21.2 million for Q1 2019.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $21.2 million in Q1 2019; TTM through Mar 2019 was $21.2 million, a N/A change from a year earlier, with the FY2018 full-year figure at $33.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities retreated to $21.2 million in Q1 2019 per TRVI's latest filing, from $33.7 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $33.7 million in Q4 2018 and bottomed at $21.2 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Trevi Therapeutics | 2.50 Bn | 2.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 21.17 Mn |
| Dec 31, 2018 | 33.69 Mn |